Drug-eluting Stent Market Increasing Demand, Growth Analysis and Future Outlook by 2031

The global drug-eluting stent market is anticipated to grow at a considerable CAGR of 7.6% during the forecast period (2024-2031). The market growth is attributed to the expanding trend in FDA approvals. As the regulatory body grants more approvals for such stents, it indicates increased acceptance and trust in the safety and efficacy of drug-eluting stents. This positive regulatory environment encourages innovation and investment in the development of new drug-eluting stent technologies. As a result, manufacturers are expanding their opportunities and market share, with healthcare providers and patients benefiting from a broader range of FDA-approved options for treating coronary artery disease.

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/drug-eluting-stent-market

• In October 2023, Medinol Ltd., obtained FDA approval for its EluNIR-PERL drug-eluting stent (DES) system to treat coronary artery disease. The stent, part of the EluNIR family, featured four radiopaque markers for enhanced visualization during procedures, aiding navigation through complex anatomies and precise stent placement.

• In May 2022, Medtronic received FDA approval for Onyx Frontier™ drug-eluting stent, part of the resolute DES family. It utilized the Resolute Onyx™ DES stent platform with an improved delivery system for enhanced deliverability and acute performance in challenging cases.

• In June 2021, Abbott Laboratories' XIENCE stents secured FDA approval for one-month DAPT labeling in high bleeding risk patients in the US, with CE Mark approval for the same globally. Additionally, FDA and CE Mark approval was granted for the next-gen XIENCE Skypoint stent, offering improved placement and enhanced expansion for treating larger blood vessels.

• In September 2021, BIOTRONIK SE & Co KG received US FDA approval for its Orsiro® Mission bioabsorbable polymer coronary drug-eluting stent system (BP-DES). The Orsiro Mission DES featured a stent design and bioabsorbable coating with controlled drugs.

Global Drug-Eluting Stent Market Report Segment

By Material

• Stainless Steel
• Cobalt-Chromium Alloy
• Others (Platinum-Chromium Alloy)

By Type

• Permanent
• Biodegradable

By Application

• Coronary Artery Stenting
• Peripheral Artery Stenting

By End-user

• Hospitals
• Cardiac Catheterization Laboratories

A full report of Drug-eluting Stent Market available @ https://www.omrglobal.com/industry-reports/drug-eluting-stent-market

Drug-eluting Stent Market Report Segment by Region

North America

• United States
• Canada

Europe

• Germany
• United Kingdom
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

• Middle East & Africa
• Latin America

Company Profiles

• Alvimedica SA
• B. Braun SE
• Biosensors International Group, Ltd.
• Cardionovum GmbH
• Cook Group Inc.
• Elixir Medical Corp.
• Hexacath
• InspireMD Inc.
• JW Medical Systems LTD.
• Lepu Medical Technology (Beijing) Co., Ltd.

Reasons to Buying From us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:

Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.

This release was published on openPR.